Mark W. Zimmerman
Dana-Farber Cancer Institute(US)Dana-Farber/Harvard Cancer Center(US)Foghorn Therapeutics (United States)(US)Dana-Farber/Boston Children's Cancer and Blood Disorders Center(US)
Publications by Year
Research Areas
Neuroblastoma Research and Treatments, Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, Virus-based gene therapy research, Chromatin Remodeling and Cancer
Most-Cited Works
- → Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry(2018)295 cited
- → MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification(2017)233 cited
- → EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma(2021)152 cited
- → Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo(2021)142 cited
- → LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis(2017)102 cited
- → ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry(2019)95 cited